Micro-X (ASX:MX1) Advances Key Programs With Multiple March Quarter Milestones

The headline framing is simple but meaningful. Micro-X has indicated that progress was achieved across several of its programs in the March quarter — not just one. That breadth matters because the company’s value proposition rests on a portfolio of applications built on its …

Sonal Goyal | 05 May 2026

Orthocell (ASX:OCC) Stock Analysis: Building a Global Footprint in Nerve Repair and Regenerative Medicine

Orthocell has communicated its first commercial sales in Canada for its nerve repair product, marking a meaningful step in the company's international commercialisation strategy. The achievement extends the geographic footprint of the product and provides another data point for investors tracking the broader regenerative …

Aditi Sarkar | 04 May 2026

Emyria (ASX:EMD) Remains on Investor Watchlists as Empax Network Strategy Scales

Mental health treatment innovation has been an area of growing investor attention, supported by the regulatory recognition of selected therapies, structured clinical models and ongoing research into novel approaches. Emyria's clinic network expansion fits within this broader theme.

Aditi Sarkar | 04 May 2026

Aroa Biosurgery (ASX:ARX) Beats Guidance as Myriad Growth Supports FY26 Performance

To appreciate the current significance of Aroa Biosurgery and its involvement with beating financial guidance driven by the growth of its Myriad product line, it is essential to consider the developmental history that precedes such announcements. Medical advancements are built upon years of rigorous …

Sonal Goyal | 04 May 2026

Dimerix (ASX:DXB) Phase III Kidney Disease Trial Draws Broker Attention

To appreciate the current significance of Dimerix and its involvement with progress in its Phase III trial for kidney disease, it is essential to consider the developmental history that precedes such announcements. Medical advancements are built upon years of rigorous preclinical testing, hypothesis formulation, …

Sonal Goyal | 04 May 2026

Orthocell (ASX:OCC) Remplir Nerve Repair Product Reports Near-90pc Success Rate

To appreciate the current significance of Orthocell and its involvement with a near-90% success rate reported for its Remplir nerve repair product, it is essential to consider the developmental history that precedes such announcements. Medical advancements are built upon years of rigorous preclinical testing, …

Sonal Goyal | 04 May 2026

LTR Pharma (ASX:LTP) SPONTAN ED Nasal Spray Shows Rapid Onset in Phase II Data

LTP’s share price dropped almost 10.78% to AUD 0.455 per share, during theTrading sessionon 4 May 2026.

Sonal Goyal | 04 May 2026

EBR Systems (ASX:EBR) Moves Closer to Australian Market After TGA Fast-Track Progress

To appreciate the current significance of EBR Systems and its involvement with TGA fast-track progress for its leadless cardiac pacing technology, it is essential to consider the developmental history that precedes such announcements. Medical advancements are built upon years of rigorous preclinical testing, hypothesis …

Sonal Goyal | 04 May 2026

Monash IVF (ASX:MVF) $300m Takeover Offer Puts Fertility Sector Back in Focus

To appreciate the current significance of Monash IVF and its involvement with a reported $300 millionTakeoveroffer putting the fertility sector back in focus, it is essential to consider the developmental history that precedes such announcements. Medical advancements are built upon years of rigorous preclinical …

Sonal Goyal | 04 May 2026

Island Pharmaceuticals (ASX:ILA) Advances Galidesivir Development After Encouraging March Quarter

To appreciate the current significance of Island Pharmaceuticals and its involvement with advancing the development of its antiviral candidate Galidesivir, it is essential to consider the developmental history that precedes such announcements. Medical advancements are built upon years of rigorous preclinical testing, hypothesis formulation, …

Sonal Goyal | 04 May 2026

Healthcare

Micro-X (ASX:MX1) Advances Key Programs With Multiple March Quarter Milestones

Orthocell (ASX:OCC) Stock Analysis: Building a Global Footprint in Nerve Repair and Regenerative Medicine

Emyria (ASX:EMD) Remains on Investor Watchlists as Empax Network Strategy Scales

Aroa Biosurgery (ASX:ARX) Beats Guidance as Myriad Growth Supports FY26 Performance

Dimerix (ASX:DXB) Phase III Kidney Disease Trial Draws Broker Attention

Orthocell (ASX:OCC) Remplir Nerve Repair Product Reports Near-90pc Success Rate

LTR Pharma (ASX:LTP) SPONTAN ED Nasal Spray Shows Rapid Onset in Phase II Data

EBR Systems (ASX:EBR) Moves Closer to Australian Market After TGA Fast-Track Progress

Monash IVF (ASX:MVF) $300m Takeover Offer Puts Fertility Sector Back in Focus

Island Pharmaceuticals (ASX:ILA) Advances Galidesivir Development After Encouraging March Quarter

Latest News

What a US fraud event means for Zip Co (ASX:ZIP) as the ASX 200 lender holds its FY27 guidance

How Xero (ASX:XRO) lifted its FY27 outlook after a Melio-driven first half

Why ASX 200 software group WiseTech Global Ltd (ASX:WTC) still faces scrutiny after ASIC closed its investigations

What the IMDA show cause notice means for Tuas Ltd (ASX:TUA) after a year of record revenue

Why Seek (ASX:SEK) Is Overhauling Its Growth Fund as the ASX 200 Jobs Marketplace Leans on Pricing

Why ASX 200 property portal REA Group (ASX:REA) is leaning on pricing as listings soften